As the COVID-19 pandemic progresses and continues to affect everyday life around the world, the path that lies ahead for the MedTech industry and the search for effective therapeutics and vaccines remains hard to predict.

The following is a small sampling of the updates compiled, reviewed and posted in real time last week by our SmartTRAK analysts. We constantly monitor  the worldwide MedTech industry, sifting through the noise to present to our subscribers the most relevant international news, trends, financial data and competitor developments in the global Life Sciences industry.

 

Companies came out of the gate strong in Q120, but COVID-19’s one-two punch on elective procedures and capital equipment purchases negatively impacted orthopedic enabling technology revenues toward the end of the quarter.

While adoption of robotics and other enabling technologies was gaining significant momentum quarter over quarter through year-end 2019, delays in elective spine surgery due to the COVID-19 pandemic resulted in declines in capital equipment sales and fewer computer-assisted orthopedic surgeries in Q120.

Among the many topics covered in the comprehensive Q120 CAS Ortho Market Recap* are:

The orthobiologics market continues to ramp up studies and new product development as surgeries impacted by COVID-19 are rescheduled. The following is a small sampling of the OrthoBio updates compiled, reviewed and posted in real time last week by our SmartTRAK analysts. We constantly monitor  the worldwide MedTech industry, sifting through the noise to present to our subscribers the most relevant international news, trends, financial data and competitor developments in the global Life Sciences industry.

A well-oiled engine, the Soft Tissue Fixation train was prepped for a good start to 2020, then COVID-19 sent it in reverse back down the revenue tracks.

Looking back at how 2019 finished, market sentiment was quite optimistic that 2020 could be another positive year for the WW Soft Tissue Fixation Market. With +3.7% YoY growth in Q419, the first quarter of 2020 seemed set for a good start, with companies chugging along nicely, actively pushing products, planning or recruiting for clinical trials, and some of them also receiving FDA 510(k) clearance for new products or for line extensions. All appeared to be business as usual, that is, until COVID-19 reared its ugly head, picking China as its first target. Alas, the rapid worldwide spread of this devastating virus forced a major halt in elective procedures to enable healthcare systems to focus on the rising number of COVID-19 cases. 

Among the many topics covered in the comprehensive Q120 Soft Tissue Fixation Market Recap* are:

The US Surgical Matrices Market treaded water in Q120, up +1.6%, as the impact of COVID-19 began to be felt broadly at the end of a quarter that had initially started with good growth.

In Q120, the US Surgical Matrices Market grew +1.6% YoY according to BioMedGPS’ SmartTRAK Financial Dashboard. Allergan* maintained its lead despite the slowdown in breast augmentation and reconstruction surgeries due to COVID-19, gaining +3.4% YoY. Becton Dickinson* (BD) also had been growing well until COVID-19 slowed hernia surgeries, and, like many other companies, warned that Q220 would be far worse since the impact of COVID-19 would be felt at the beginning of the quarter.

Among the many topics covered in the comprehensive Q120 US Surgical Matrices Market Recap* are:

The mid-March madness of COVID-19 results in final missed shots for many companies.

For sports fans, March is about celebrating the best in college basketball. Regrettably, March Madness was swapped with COVID-19 mid-March madness, disrupting lives and companies across the world. Since the COVID-19 outbreak, the first corporate earnings season has concluded and we now have a peek of the negative impacts caused by the pandemic and deferral of elective procedures. As for Q120, US orthobiologics revenue declined -5.5% YoY compared to Q119. 

Among the many topics covered in the comprehensive Q120 OrthoBio Market Recap* are:

As COVID-19 surges in the United States and around the world, health officials are responding with stern warnings, more testing and cutbacks on closings. While some nations have virtually stopped the spread within their country, MedTech prepares for a post-COVID world and how the virus and the response to it will reshape the industry.

The following is a small sampling of the COVID-19 updates compiled, reviewed and posted in real-time by our SmartTRAK analysts, who are constantly monitoring the situation and sifting through the noise to present the most relevant news to our subscribers:

Q120 remained a bright spot showing positive growth with modest disruption from COVID-19 for the quarter.

For Q120, according to BioMedGPS’ SmartTRAK Financial Dashboard, the US Infection Prevention - Vascular Access Adjunct Products market was up +4. 4% YoY. The prevention of Hospital-Acquired Infections (HAIs) continues to drive measures and practices to reduce Central Line-Associated Bloodstream Infections (CLABSIs) and is creating demand for products that can address these issues. Numerous programs and educational tools are being developed to provide measures and strategies that assist healthcare providers in the prevention and reduction of infection in acute care and other settings.

Among the many topics covered in the comprehensive Q120 Infection Prevention: Vascular Access Adjunct Products Recap Market Recap* are:

The US market for Hemostats and Sealants grew +6.1% YoY in Q120, up from the pace of Q419 despite the late appearance of COVD-19 in the last few weeks of the quarter. Growth was slightly higher in the Hemostats market, with +6.8% growth driven by relative strength in thrombin hemostats.

As reported in SmartTRAK Financial Dashboard, the US Hemostats and Sealants market had a growth rate of +6.1% in Q120. Leading the way in Q120 was Baxter* with +11.6% YoY growth and continued strength from Tisseel* and Artiss* fibrin sealants. Becton Dickinson* (BD) also posted strong gains as its relaunched Progel* and continued its resurgence in Q120. However, all manufacturers predicted that second-quarter results would be much worse since the full effect of surgery deferrals would be felt for the entire quarter. Some manufacturers warned that revenues were reduced as much as...

Among the many topics covered in the comprehensive Q120 Hemostats and Sealants Market Recap* are:

The SCS market saw double-digit declines in Q120 as elective procedures fell off a cliff toward the end of the quarter due to COVID-19

After a disappointing slowdown in 2019, the spinal cord stimulation (SCS) market was positioned for growth in Q120 after a successful North American Neuromodulation Society (NANS) Annual Meeting in January 2020. With new data and products providing an early tailwind for all SCS competitors, companies reported positive momentum until approximately the third week of March when COVID-19 led to shelter-in-place orders and a sharp decline in elective procedures. This effectively put a halt to the vast majority of SCS trials and implants in the US and also impacted companies with SCS sales in China during January and February ...

Among the many topics covered in the comprehensive Q120 Spinal Cord Stimulation (SCS) Market Recap* are: